Compare Novartis with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ORCHID PHARMA LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ORCHID PHARMA LTD NOVARTIS/
ORCHID PHARMA LTD
 
P/E (TTM) x 493.9 -0.5 - View Chart
P/BV x 28.7 0.1 24,324.9% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ORCHID PHARMA LTD
Sep-13
NOVARTIS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs758194 390.7%   
Low Rs57935 1,654.3%   
Sales per share (Unadj.) Rs228.4276.5 82.6%  
Earnings per share (Unadj.) Rs31.7-79.2 -40.1%  
Cash flow per share (Unadj.) Rs32.8-43.5 -75.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.153.9 550.9%  
Shares outstanding (eoy) m24.6970.45 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.90.4 706.8%   
Avg P/E ratio x21.1-1.4 -1,457.1%  
P/CF ratio (eoy) x20.4-2.6 -774.3%  
Price / Book Value ratio x2.22.1 106.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5058,067 204.6%   
No. of employees `0000.72.8 23.9%   
Total wages/salary Rs m1,4452,527 57.2%   
Avg. sales/employee Rs Th8,441.36,956.1 121.4%   
Avg. wages/employee Rs Th2,163.6902.5 239.7%   
Avg. net profit/employee Rs Th1,173.1-1,993.0 -58.9%   
INCOME DATA
Net Sales Rs m5,63919,477 29.0%  
Other income Rs m1,718407 422.0%   
Total revenues Rs m7,35719,884 37.0%   
Gross profit Rs m-631,103 -5.7%  
Depreciation Rs m252,519 1.0%   
Interest Rs m555,227 1.1%   
Profit before tax Rs m1,575-6,236 -25.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m792-125 -632.3%   
Profit after tax Rs m784-5,580 -14.0%  
Gross profit margin %-1.15.7 -19.6%  
Effective tax rate %50.32.0 2,503.1%   
Net profit margin %13.9-28.7 -48.5%  
BALANCE SHEET DATA
Current assets Rs m9,52211,014 86.4%   
Current liabilities Rs m3,29632,060 10.3%   
Net working cap to sales %110.4-108.1 -102.2%  
Current ratio x2.90.3 840.9%  
Inventory Days Days3795 38.6%  
Debtors Days Days2834 84.7%  
Net fixed assets Rs m4629,440 0.2%   
Share capital Rs m123705 17.5%   
"Free" reserves Rs m7,2132,043 353.1%   
Net worth Rs m7,3363,800 193.1%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m11,10546,510 23.9%  
Interest coverage x29.5-0.2 -15,267.5%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.50.4 121.3%   
Return on assets %7.6-0.8 -993.9%  
Return on equity %10.7-146.9 -7.3%  
Return on capital %22.2-3.7 -595.1%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m617,513 0.8%   
Fx outflow Rs m3,6305,649 64.3%   
Net fx Rs m-3,5701,865 -191.5%   
CASH FLOW
From Operations Rs m1,6101,682 95.7%  
From Investments Rs m687-9,860 -7.0%  
From Financial Activity Rs m-2,6776,644 -40.3%  
Net Cashflow Rs m-380-1,535 24.7%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.6 43.5%  
FIIs % 1.6 3.3 48.5%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.5 55.3 38.9%  
Shareholders   41,647 84,811 49.1%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PLETHICO PHARMA  WOCKHARDT  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Falling Gold Prices, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Thursday, Indian share markets witnessed negative trading activity throughout the day and ended deep in the red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - NATCO PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS